A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Anlotinib (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 23 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2016 Status changed from not yet recruiting to recruiting.
- 09 Dec 2015 New trial record